A groundbreaking advancement in medical technology is poised to revolutionize the diagnosis of high blood pressure, a pervasive health concern affecting millions worldwide. Researchers have developed a wearable device capable of continuously monitoring hormone fluctuations throughout the day and night, offering a critical new tool for identifying primary aldosteronism, a hormone disorder often missed by conventional diagnostic methods. This innovative approach holds the potential to significantly improve patient outcomes by enabling earlier intervention and reducing the risk of severe cardiovascular complications.
The Silent Threat of Primary Aldosteronism
Primary aldosteronism, a condition characterized by the overproduction of aldosterone by the adrenal glands, can affect a substantial portion of individuals diagnosed with hypertension. Estimates suggest it may be present in as many as one in five people with elevated blood pressure. Aldosterone plays a crucial role in regulating the body’s salt and water balance, and its excess can lead to increased blood volume and, consequently, heightened blood pressure.
Beyond the immediate concern of hypertension, primary aldosteronism is a significant risk factor for a cascade of serious health problems. These include an elevated risk of heart disease, stroke, the development of diabetes, and chronic kidney disease. Despite its prevalence and the severity of its associated risks, primary aldosteronism remains notoriously underdiagnosed. This diagnostic challenge is largely attributed to the complex and fluctuating nature of hormone production, which often falls outside the scope of standard, single-point blood tests.
A Paradigm Shift in Hormone Monitoring
The research, a collaborative effort involving esteemed institutions such as the University of Bristol and the University of Manchester in the UK, the University of Bergen in Norway, and contributing researchers from Stockholm and Athens, has unveiled a critical insight: individuals with primary aldosteronism experience distinct surges in hormone production, not only during waking hours but also during sleep. These nocturnal surges are particularly significant because conventional diagnostic protocols typically do not involve blood sampling during sleep.
To overcome this diagnostic hurdle, the research team harnessed a novel wearable device, pioneered at the University of Bristol. This sophisticated yet portable technology allows for continuous, real-time monitoring of hormone levels in patients while they live their normal daily lives. This departure from traditional hospital-bound diagnostics offers a more accurate and representative picture of the body’s hormonal activity in naturalistic settings.
Dr. Thomas Upton, a Clinical Research Fellow at the University of Bristol and a co-lead author of the study, emphasized the profound implications of this new approach. "Primary aldosteronism is an important cause of high blood pressure and the most common cause of secondary hypertension we see in our blood pressure clinic," Dr. Upton stated. "It could be affecting millions of people in the UK. However, due to the way hormones change during the day and the current complexity of the diagnostic process, diagnosis is often delayed or never made at all."
He further elaborated on the advantages of at-home monitoring: "In our study, patients were monitored at home during normal activity, and this allowed us to see how hormones changed over time in realistic settings. This approach could potentially revolutionize how we diagnose hypertension and ultimately reduce cardiovascular disease – particularly heart disease and strokes – that could have been prevented."
The U-RHYTHM Technology: Capturing the Unseen
The proof-of-concept study involved 60 participants across Bristol, Bergen, Stockholm, and Athens, each monitored for a 24-hour period. The core of this extensive data collection was the U-RHYTHM technology, a lightweight wearable device approximately the size of a mobile phone, which attaches to the waist. This device meticulously sampled hormone levels every 20 minutes.
A key innovation of the U-RHYTHM system is its ability to collect hormonal data through the skin, a minimally invasive method that allows participants to maintain their usual routines, including sleeping soundly throughout the night. This continuous sampling strategy is crucial for capturing the transient hormonal shifts that can elude standard blood tests. The U-RHYTHM technology itself has a lineage of development, having been adopted and further enhanced by the spinout company Dynamic Therapeutics in 2023, underscoring its commercial and clinical potential.
Dr. Eder Zavala, a UKRI Future Leader Fellow at the University of Manchester and senior author of the study, highlighted the scientific significance of the findings. "By continuously monitoring hormones over 24 hours, we were able to reveal a previously hidden pattern of nocturnal hormone bursts. This gives us a much clearer understanding of the disease and could ultimately help doctors detect it earlier and treat patients more effectively," Dr. Zavala explained. He further suggested that "A more detailed mathematical and computational analysis of daily hormonal profiles could eventually also help uncover earlier and more subtle forms of the disease, opening new opportunities to improve outcomes for patients living with high blood pressure."
Why Traditional Methods Fall Short
The prevailing diagnostic methods for primary aldosteronism typically rely on analyzing aldosterone levels in blood or urine samples. However, these approaches often fail to detect the condition due to the pulsatile nature of aldosterone secretion. Aldosterone does not remain at a consistently elevated level; instead, it is released in bursts. This means a single blood test, taken at an arbitrary moment, might capture a period when aldosterone levels are temporarily within the normal range, leading to a false negative result.
The research team employed sophisticated computational analysis to meticulously track changes in aldosterone, as well as two closely related hormones: 18-hydroxycortisol and 18-oxocortisol. These companion hormones are vital indicators because their secretion patterns are intrinsically linked to aldosterone production. The study’s findings strongly suggest that current diagnostic protocols are insufficient because they do not account for the dynamic, rhythmic nature of hormone release. Even in severe cases of primary aldosteronism, hormone levels could dip below the established diagnostic thresholds at certain times.
The study revealed a distinct pattern: aldosterone exhibited repeated surges of secretion during the night, while the overall daily rhythm of hormone activity remained largely intact. This nocturnal surge, a previously underappreciated phenomenon, offers a critical new diagnostic clue.
Nocturnal Surges: A Critical Diagnostic Indicator
These pronounced nighttime hormone spikes were found to originate from the adrenal glands. Notably, the intensity of these nocturnal surges was particularly pronounced in patients whose primary aldosteronism stemmed from a unilateral issue – meaning a problem affecting only one adrenal gland, as opposed to both.
Crucially, the study observed that these abnormal hormonal patterns disappeared following the surgical removal of the affected adrenal gland. This outcome provided compelling evidence directly linking the observed hormone bursts to the presence of the disease, solidifying the diagnostic significance of these nocturnal fluctuations.
Professor Stafford Lightman, a Professor of Medicine at the University of Bristol and the inventor of the U-RHYTHM technology, underscored the need for a paradigm shift in clinical practice. "The findings suggest that clinicians may need to rethink how they look for the disorder, which the Endocrine Society clinical practice guidelines now recommend should be considered for all people with hypertension, also known as high blood pressure," Professor Lightman stated.
He further elaborated on the future trajectory of diagnosis: "Future diagnosis could move away from single time point blood tests and towards tracking the body’s hormone rhythms over time, particularly the overnight patterns that appear to hold crucial clues to disease. Further research is needed to define the best clinical pathways, using dynamic hormone measurement, to ensure early diagnosis of this common and potentially curable cause of high blood pressure."
Implications for Public Health and Cardiovascular Disease Prevention
The implications of this research are far-reaching, promising a future where the diagnosis of primary aldosteronism is more accurate, timely, and less burdensome for patients. By shifting the diagnostic paradigm from static, single-point measurements to dynamic, continuous monitoring of hormone rhythms, particularly during the critical overnight period, healthcare professionals can gain unprecedented insight into the underlying causes of hypertension.
The potential for earlier detection of primary aldosteronism carries significant weight given that the condition is often treatable and, in some cases, potentially curable. Early intervention can effectively manage blood pressure and, more importantly, mitigate the risk of developing life-threatening cardiovascular complications such as heart attacks and strokes. This proactive approach aligns with global efforts to reduce the burden of cardiovascular disease, which remains a leading cause of mortality worldwide.
The funding for this groundbreaking research was provided by a consortium of esteemed organizations, including EU Horizon 2020, the Trond Mohn Foundation, the UKRI Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council, University Hospitals Bristol and Weston NHS Foundation, the Swedish Medical Research Council, and the Knut and Alice Wallenberg Foundation. These contributions highlight the international commitment to advancing our understanding and treatment of cardiovascular health.
The findings also strongly support the University of Bristol’s strategic research focus on "Understanding and Preventing Cardiovascular Disease," a key component of its ‘Grand Challenge’ initiative. Furthermore, this work builds upon existing National Institute for Health Research (NIHR)-funded programs aimed at improving the early identification of individuals at risk for hypertension and other cardiovascular risk factors, reinforcing a concerted effort to enhance preventive cardiology.
The development and validation of wearable hormone-monitoring technology represent a significant leap forward, offering a tangible solution to a long-standing diagnostic challenge. As this technology becomes more widely accessible, it has the potential to transform the management of hypertension, leading to improved health outcomes and a reduced incidence of cardiovascular morbidity and mortality globally. The transition from a reactive approach to a more proactive, data-driven diagnostic strategy promises a healthier future for millions.
